Veristrat(®) Classifier for Survival and Time to Progression in Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Erlotinib and Bevacizumab

We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat(®)) in a blinded manner to pre-treatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Carbone, David P., Salmon, J. Stuart, Billheimer, Dean, Chen, Heidi, Sandler, Alan, Roder, Heinrich, Roder, Joanna, Tsypin, Maxim, Herbst, Roy S., Tsao, Anna S., Tran, Hai T., Dang, Thao P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2891357/
https://ncbi.nlm.nih.gov/pubmed/20036440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2009.11.019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados